Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by RAJAT J KUDCHADKER and STEVEN JAY FRANK.
RAJAT J KUDCHADKER
Connection Strength
7.018
STEVEN JAY FRANK
  1. Preoperative treatment planning with intraoperative optimization can achieve consistent high-quality implants in prostate brachytherapy. Med Dosim. 2012; 37(4):387-90.
    View in: PubMed
    Score: 0.419
  2. Is a loose-seed nomogram still valid for prostate brachytherapy in a stranded-seed era? Int J Radiat Oncol Biol Phys. 2008 Oct 01; 72(2):623-7.
    View in: PubMed
    Score: 0.316
  3. A Novel Polymer-Encapsulated Multi-Imaging Modality Fiducial Marker with Positive Signal Contrast for Image-Guided Radiation Therapy. Cancers (Basel). 2024 Jan 31; 16(3).
    View in: PubMed
    Score: 0.236
  4. Uncertainty in magnetic resonance imaging-based prostate postimplant dosimetry: Results of a 10-person human observer study, and comparisons with automatic postimplant dosimetry. Brachytherapy. 2023 Nov-Dec; 22(6):822-832.
    View in: PubMed
    Score: 0.230
  5. Prospective Evaluation of Prostate and Organs at Risk Segmentation Software for MRI-based Prostate Radiation Therapy. Radiol Artif Intell. 2022 Mar; 4(2):e210151.
    View in: PubMed
    Score: 0.206
  6. Computer-aided segmentation on MRI for prostate radiotherapy, part II: Comparing human and computer observer populations and the influence of annotator variability on algorithm variability. Radiother Oncol. 2022 04; 169:132-139.
    View in: PubMed
    Score: 0.205
  7. Computer-aided segmentation on MRI for prostate radiotherapy, Part I: Quantifying human interobserver variability of the prostate and organs at risk and its impact on radiation dosimetry. Radiother Oncol. 2022 04; 169:124-131.
    View in: PubMed
    Score: 0.204
  8. Improving efficiency and reducing costs of MRI-Guided prostate brachytherapy using Time-Driven Activity-Based costing. Brachytherapy. 2022 Jan-Feb; 21(1):49-54.
    View in: PubMed
    Score: 0.199
  9. The American Brachytherapy Society prostate brachytherapy LDR/HDR simulation workshops: Hands-on, step-by-step training in the process of quality assurance. Brachytherapy. 2020 Nov - Dec; 19(6):787-793.
    View in: PubMed
    Score: 0.189
  10. Fully Balanced SSFP Without an Endorectal Coil for Postimplant QA of MRI-Assisted Radiosurgery (MARS) of Prostate Cancer: A Prospective Study. Int J Radiat Oncol Biol Phys. 2021 02 01; 109(2):614-625.
    View in: PubMed
    Score: 0.187
  11. Outcomes and Toxicities of Proton and Photon Radiation Therapy for Testicular Seminoma. Int J Part Ther. 2020; 7(2):11-20.
    View in: PubMed
    Score: 0.187
  12. Development, implementation, and outcomes of a simulation-based medical education (SBME) prostate brachytherapy workshop for radiation oncology residents. Brachytherapy. 2020 Nov - Dec; 19(6):738-745.
    View in: PubMed
    Score: 0.187
  13. Predictors of urinary toxicity with MRI-assisted radiosurgery for low-dose-rate prostate brachytherapy. Brachytherapy. 2020 Sep - Oct; 19(5):574-583.
    View in: PubMed
    Score: 0.185
  14. Machine Segmentation of Pelvic Anatomy in MRI-Assisted Radiosurgery (MARS) for Prostate Cancer Brachytherapy. Int J Radiat Oncol Biol Phys. 2020 12 01; 108(5):1292-1303.
    View in: PubMed
    Score: 0.185
  15. MRI-assisted radiosurgery: A quality assurance nomogram for palladium-103 and iodine-125 prostate brachytherapy. Brachytherapy. 2020 Jan - Feb; 19(1):38-42.
    View in: PubMed
    Score: 0.177
  16. Patient-reported health-related quality of life for men treated with low-dose-rate prostate brachytherapy as monotherapy with 125-iodine, 103-palladium, or 131-cesium: Results of a prospective phase II study. Brachytherapy. 2018 Mar - Apr; 17(2):265-276.
    View in: PubMed
    Score: 0.155
  17. Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes. Int J Radiat Oncol Biol Phys. 2018 02 01; 100(2):374-382.
    View in: PubMed
    Score: 0.153
  18. Permanent prostate brachytherapy postimplant magnetic resonance imaging dosimetry using positive contrast magnetic resonance imaging markers. Brachytherapy. 2017 Jul - Aug; 16(4):761-769.
    View in: PubMed
    Score: 0.148
  19. Permanent prostate brachytherapy pubic arch evaluation with diagnostic magnetic resonance imaging. Brachytherapy. 2017 Jul - Aug; 16(4):728-733.
    View in: PubMed
    Score: 0.147
  20. Pulse sequence considerations for simulation and postimplant dosimetry of prostate brachytherapy. Brachytherapy. 2017 Jul - Aug; 16(4):743-753.
    View in: PubMed
    Score: 0.145
  21. Effect of pulse sequence parameter selection on signal strength in positive-contrast MRI markers for MRI-based prostate postimplant assessment. Med Phys. 2016 Jul; 43(7):4312.
    View in: PubMed
    Score: 0.140
  22. Development of a magnetic resonance imaging protocol to visualize encapsulated contrast agent markers in prostate brachytherapy recipients: initial patient experience. J Contemp Brachytherapy. 2016 Jun; 8(3):235-42.
    View in: PubMed
    Score: 0.139
  23. Defining the value framework for prostate brachytherapy using patient-centered outcome metrics and time-driven activity-based costing. Brachytherapy. 2016 May-Jun; 15(3):274-282.
    View in: PubMed
    Score: 0.136
  24. Evaluation of the MIM Symphony treatment planning system for low-dose-rate- prostate brachytherapy. J Appl Clin Med Phys. 2015 09 08; 16(5):62?75.
    View in: PubMed
    Score: 0.132
  25. Sexual potency preservation and quality of life after prostate brachytherapy and low-dose tadalafil. Brachytherapy. 2015 Mar-Apr; 14(2):160-5.
    View in: PubMed
    Score: 0.124
  26. Establishing high-quality prostate brachytherapy using a phantom simulator training program. Int J Radiat Oncol Biol Phys. 2014 Nov 01; 90(3):579-86.
    View in: PubMed
    Score: 0.123
  27. MRI characterization of cobalt dichloride-N-acetyl cysteine (C4) contrast agent marker for prostate brachytherapy. Phys Med Biol. 2014 May 21; 59(10):2505-16.
    View in: PubMed
    Score: 0.120
  28. MRI-based sector analysis enhances prostate palladium-103 brachytherapy quality assurance in a phase II prospective trial of men with intermediate-risk localized prostate cancer. Brachytherapy. 2014 Jan-Feb; 13(1):68-74.
    View in: PubMed
    Score: 0.112
  29. An MRI-based dose--reponse analysis of urinary sphincter dose and urinary morbidity after brachytherapy for prostate cancer in a phase II prospective trial. Brachytherapy. 2013 May-Jun; 12(3):210-6.
    View in: PubMed
    Score: 0.111
  30. Improving prostate brachytherapy quality assurance with MRI-CT fusion-based sector analysis in a phase II prospective trial of men with intermediate-risk prostate cancer. Brachytherapy. 2013 Sep-Oct; 12(5):401-7.
    View in: PubMed
    Score: 0.110
  31. Magnetic resonance imaging-based treatment planning for prostate brachytherapy. Brachytherapy. 2013 Jan-Feb; 12(1):30-7.
    View in: PubMed
    Score: 0.106
  32. Sexual function and the use of medical devices or drugs to optimize potency after prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2012 Apr 01; 82(5):e765-71.
    View in: PubMed
    Score: 0.103
  33. Screening colonoscopy before prostate cancer treatment can detect colorectal cancers in asymptomatic patients and reduce the rate of complications after brachytherapy. Pract Radiat Oncol. 2012 Jul-Sep; 2(3):e7-e13.
    View in: PubMed
    Score: 0.102
  34. Long-term tumor control after brachytherapy for base-of-prostate cancer. J Contemp Brachytherapy. 2011 Dec; 3(4):183-7.
    View in: PubMed
    Score: 0.102
  35. Displacement of periurethral stranded seeds and its dosimetric consequences in prostate brachytherapy. Brachytherapy. 2011 Sep-Oct; 10(5):401-8.
    View in: PubMed
    Score: 0.096
  36. Impact of urinary catheterization on dosimetry after prostate implant brachytherapy with palladium-103 or iodine-125. Brachytherapy. 2011 Jul-Aug; 10(4):269-74.
    View in: PubMed
    Score: 0.096
  37. Anisotropy characterization of I-125 seed with attached encapsulated cobalt chloride complex contrast agent markers for MRI-based prostate brachytherapy. Med Dosim. 2011; 36(2):200-5.
    View in: PubMed
    Score: 0.092
  38. A volumetric trend analysis of the prostate and seminal vesicles during a course of intensity-modulated radiation therapy. Am J Clin Oncol. 2010 Apr; 33(2):173-5.
    View in: PubMed
    Score: 0.091
  39. Urinary side effects and complications after permanent prostate brachytherapy: the MD Anderson Cancer Center experience. Urology. 2009 Sep; 74(3):601-5.
    View in: PubMed
    Score: 0.086
  40. Late rectal complications after prostate brachytherapy for localized prostate cancer: incidence and management. Cancer. 2009 May 01; 115(9):1827-39.
    View in: PubMed
    Score: 0.085
  41. Prostogram predicted brachytherapy outcomes are not universally accurate: an analysis based on the M. D. Anderson Cancer Center experience with (125)iodine brachytherapy. J Urol. 2009 Apr; 181(4):1658-63; discussion 1663-4.
    View in: PubMed
    Score: 0.084
  42. A novel MRI marker for prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2008 May 01; 71(1):5-8.
    View in: PubMed
    Score: 0.079
  43. Quantification of prostate and seminal vesicle interfraction variation during IMRT. Int J Radiat Oncol Biol Phys. 2008 Jul 01; 71(3):813-20.
    View in: PubMed
    Score: 0.078
  44. Quality comparison between three-dimensional T2-weighted SPACE and two-dimensional T2-weighted turbo spin echo magnetic resonance images for the brachytherapy planning evaluation of prostate and periprostatic anatomy. Brachytherapy. 2020 Jul - Aug; 19(4):484-490.
    View in: PubMed
    Score: 0.046
  45. Deep learning application engine (DLAE): Development and integration of deep learning algorithms in medical imaging. SoftwareX. 2019 Jul-Dec; 10.
    View in: PubMed
    Score: 0.044
  46. Development and clinical implementation of SeedNet: A sliding-window convolutional neural network for radioactive seed identification in MRI-assisted radiosurgery (MARS). Magn Reson Med. 2019 06; 81(6):3888-3900.
    View in: PubMed
    Score: 0.042
  47. Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer. J Clin Oncol. 2018 10 10; 36(29):2943-2949.
    View in: PubMed
    Score: 0.040
  48. Patient-reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity-modulated Radiation Therapy for Prostate Cancer: Results From a Randomized Trial. Am J Clin Oncol. 2018 Jun; 41(6):558-567.
    View in: PubMed
    Score: 0.040
  49. A methodology to investigate the impact of image distortions on the radiation dose when using magnetic resonance images for planning. Phys Med Biol. 2018 04 05; 63(8):085005.
    View in: PubMed
    Score: 0.039
  50. Comparison of prostate distortion by inflatable and rigid endorectal MRI coils in permanent prostate brachytherapy imaging. Brachytherapy. 2018 Mar - Apr; 17(2):298-305.
    View in: PubMed
    Score: 0.038
  51. Prostate brachytherapy, either alone or in combination with external beam radiation, is associated with longer overall survival in men with favorable pathologic Group 4 (Gleason score 8) prostate cancer. Brachytherapy. 2017 Jul - Aug; 16(4):790-796.
    View in: PubMed
    Score: 0.037
  52. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Int J Radiat Oncol Biol Phys. 2014 Apr 01; 88(5):1074-84.
    View in: PubMed
    Score: 0.030
  53. Factors associated with improved biochemical response to neoadjuvant androgen deprivation therapy before definitive radiation therapy in prostate cancer patients. Prostate Cancer Prostatic Dis. 2013 Dec; 16(4):346-51.
    View in: PubMed
    Score: 0.029
  54. A novel dose-based positioning method for CT image-guided proton therapy. Med Phys. 2013 May; 40(5):051714.
    View in: PubMed
    Score: 0.028
  55. PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era. Int J Radiat Oncol Biol Phys. 2013 Jan 01; 85(1):e39-46.
    View in: PubMed
    Score: 0.027
  56. Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: implications for prostate brachytherapy. Brachytherapy. 2013 May-Jun; 12(3):204-9.
    View in: PubMed
    Score: 0.026
  57. Dosimetric impact of fiducial markers in patients undergoing photon beam radiation therapy. Phys Med. 2012 Jul; 28(3):240-4.
    View in: PubMed
    Score: 0.025
  58. Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2007 Mar 15; 67(4):1059-65.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.